Friend or Foe: The Use of Cannabis as a Potential Analgesic in Postoperative Lumbar Spine Surgery.
| Audience | Patients, clinicians, healthcare professionals, regulators, and industry researchers. |
| Primary Topic | Clinical and policy analysis: Friend or Foe: The Use of Cannabis as a Potential Analg. |
| Source | Read the full source |
Friend or Foe: The Use of Cannabis as a Potential Analgesic in Postoperative Lumbar Spine Surgery.
A structured CED Clinic overview of 3 key developments in cannabis regulation, market milestones, and scientific research.
| Post Type | Cannabis Science & Research Digest using canonical CED layout |
| Items Reviewed | 3 verified updates |
| Primary Dates | October 23, 2026 |
| Related Reading | 3 verified live CED Clinic internal links |
| Update 1 | Real-world substance use in body (Jonathan et al., Body image) [DOI: 10.1016/j.bodyim.2026.102197 | PMID: 42892277] |
| Update 2 | Substance use diagnoses among patients (Ramdin et al., Journal of addictive diseases) [DOI: 10.1080/10550887.2026.2733227 | PMID: 42878529] |
| Update 3 | Friend or Foe: The Use (Tuluca et al., Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews) [DOI: 10.5435/JAAOSGlobal-D-25-00326 | PMID: 42878555] |
This curated cannabis science & research digest brings together 3 key developments across clinical investigations, epidemiological surveys, and therapeutic data. Reviewing these distinct updates side by side clarifies emerging patterns while preserving the specific clinical context of each report.
Examining these developments concurrently helps clinicians, patients, and families trace the broader trajectory of the field while grounding practical decisions in verified primary data.
Title & Source: Real-world substance use in body dysmorphic disorder: An ecological momentary assessment study of motives, contexts, and suicidal ideation. (Body image, 2026Oct17)
Lead Authors & Identifiers: Geneva K Jonathan, Sara Velazquez, A Eden Evins, Bettina B Hoeppner et al.. | Primary Record: DOI: 10.1016/j.bodyim.2026.102197 | PMID: 42892277 Content lane: Evidence Check.
Investigational Focus: This study used ecological momentary assessment to track 87 adults with body dysmorphic disorder over 28 days. The researchers examined the motives and contexts of alcohol and cannabis use in real-time.
Key Findings & Primary Data: Among the participants, 67.8% reported substance use. Coping-motivated surveys were associated with a three- to four-fold increase in the odds of suicidal desire compared to other motives.
Clinical Guidance: Clinicians should screen for coping-motivated substance use as a potential marker for suicide risk in patients with body dysmorphic disorder. Social or relaxation motives do not appear to carry the same level of risk.
Study Boundaries: The study relied on a relatively small sample size and self-reported data. The findings may not generalize to all individuals with body dysmorphic disorder.
Title & Source: Substance use diagnoses among patients who present to federally run mental health facilities with co-morbid ADHD and bipolar disorder between 2013-2023: a national analysis using random forest methods. (Journal of addictive diseases, 2026Oct15)
Lead Authors & Identifiers: Christine Ramdin, Jamey J Lister, Ellen Kurtzman, Sally Kuo et al.. | Primary Record: DOI: 10.1080/10550887.2026.2733227 | PMID: 42878529 Content lane: Safety Signal.
Investigational Focus: Researchers analyzed national mental health data from 2013 to 2023 to identify trends in substance use among patients with comorbid ADHD and bipolar disorder. The study utilized random forest models to identify key predictors of these diagnoses.
Key Findings & Primary Data: The analysis included 5,691 patients, all of whom had a documented substance use disorder. Cannabis dependence was the third most common specific diagnosis, affecting 7.9% of the cohort.
Clinical Guidance: Patients with comorbid ADHD and bipolar disorder require integrated screening for substance use disorders. Employment status and education level were identified as significant predictors of these co-occurring conditions.
Study Boundaries: The data was limited to patients at federally run facilities. This may not reflect the prevalence or trends in the general population or private healthcare settings.
Title & Source: Friend or Foe: The Use of Cannabis as a Potential Analgesic in Postoperative Lumbar Spine Surgery. (Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026Oct01)
Lead Authors & Identifiers: Andrei Tuluca, Jonathan Boyce, Gregory Schneider, Eric A Williams. | Primary Record: DOI: 10.5435/JAAOSGlobal-D-25-00326 | PMID: 42878555 Content lane: Clinical Evidence Update.
Investigational Focus: This literature review evaluated the evidence for using cannabis as an analgesic following lumbar spine surgery. The authors sought to consolidate current research on perioperative cannabis utility and identify gaps in the evidence.
Key Findings & Primary Data: The review found conflicting research regarding the benefits and risks of cannabis use in surgical patients. There is currently a lack of Level I evidence to support definitive clinical recommendations for its use as a postoperative pain mitigator.
Clinical Guidance: Surgeons should engage in open discussions with patients about their cannabis use while acknowledging the current uncertainty in the literature. A cautious approach is warranted until more rigorous clinical trials are completed.
Study Boundaries: The review is limited by the quality of the underlying studies, which are often retrospective or observational. The lack of standardized dosing and formulations in the literature makes it difficult to draw firm conclusions.
The intersection of cannabis use and complex psychiatric profiles is becoming a focal point of modern behavioral health. As more patients with multifaceted diagnoses like ADHD and bipolar disorder gain access to legal cannabis, the clinical community faces the challenge of distinguishing between therapeutic use and maladaptive coping. This distinction is vital for providing safe and effective care in an era of increasing availability.
Simultaneously, the surgical community is grappling with the lack of standardized protocols for perioperative cannabis management. The shift away from opioids has accelerated interest in alternatives, yet the clinical data remains fragmented. This leaves both surgeons and patients in a state of uncertainty regarding optimal dosing and timing for pain management during recovery.
When I talk with patients who have complex mental health histories, the conversation usually centers on why they are reaching for a product at a specific moment. If the goal is to quiet a mind racing from ADHD or to soften the edges of a depressive episode, the risk profile changes. The data showing that coping-motivated use correlates with suicidal desire is a sobering reminder that the intent matters just as much as the substance.
In the surgical realm, the tension is real. Patients are often told to stop all cannabis use before a procedure due to anesthesia concerns, yet they are left without a plan for managing the pain that cannabis was helping them endure. We need to bridge this gap with more nuanced, patient-centered research that respects the reality of their lived experience. Rigid rules often fail to account for the complex needs of the individual.
How to Interpret This Cannabis Science & Research Digest
Clinical decision-making requires balancing large-scale trends with the intimate, day-to-day realities of patient behavior.
Three Rules for Critical Reading
Contextualize the Motive
Look beyond the frequency of use to understand if a patient is seeking social connection or escaping emotional pain.
Recognize Comorbidity Risks
Acknowledge that patients with multiple psychiatric diagnoses are statistically more likely to develop dependence.
Demand Better Data
Question the lack of controlled trials in surgical settings before making rigid recommendations for or against use.
CED Perspective Lens: Eight Viewpoints on These Updates
Why these developments matter across clinical, patient, safety, and policy perspectives
Understanding Your Motives
Understanding why you reach for cannabis is just as important as the dose you take. If you find yourself using it to escape difficult emotions or thoughts about your appearance, it may be a sign that you need more support. This research shows that using cannabis for coping can sometimes be linked to deeper distress.
Talk openly with your care team about your goals for using cannabis, especially if you are preparing for a major surgery. Being honest about your habits helps your doctors keep you safe during anesthesia and recovery. Your safety depends on a clear plan that addresses both your physical pain and your mental well-being.
Screening for Risk
Screening for substance use in patients with complex psychiatric comorbidities like ADHD and bipolar disorder is essential. These patients are at a higher risk for dependence, and their motives for use can provide critical insights into their mental state. Coping-motivated use should be viewed as a potential indicator of increased suicide risk.
In the absence of Level I evidence for surgical patients, clinicians must rely on thorough histories and patient-centered discussions. Balancing the potential for pain relief with the risks of perioperative complications requires a nuanced approach. Stay informed about emerging data to provide the best guidance for those navigating recovery.
Context and Complications
Safety in cannabis use is about the product itself and the psychological context of the user. Patients using cannabis to manage severe emotional distress may be at a higher risk for self-harm. Monitoring these patients closely during periods of high stress or after major life events is a necessary precaution.
For surgical patients, the lack of clear evidence on cannabis and anesthesia creates a safety gap. Until more rigorous studies are available, the safest approach involves early disclosure and collaborative planning between the patient and the surgical team. This ensures that all potential interactions and recovery needs are addressed.
Integrated Care Needs
National data shows a steady increase in complex psychiatric patients with substance use disorders. This trend highlights the need for integrated mental health and addiction services within federal and state healthcare systems. Policy should focus on expanding access to comprehensive care that addresses the root causes of substance use.
The lack of Level I evidence for cannabis in surgical settings is a direct result of its long-standing regulatory status. Rescheduling and increased funding for clinical trials are necessary to provide the data that surgeons and patients need. Clearer guidelines will only emerge when the research community can study these products without barriers.
Closing the Evidence Gap
Ecological momentary assessment offers a powerful tool for understanding the real-time dynamics of substance use. Future research should continue to use these methods to explore the relationship between specific psychiatric symptoms and cannabis use patterns. This high-resolution data is essential for developing targeted interventions for at-risk populations.
The surgical community desperately needs randomized controlled trials to evaluate the efficacy and safety of cannabis for postoperative pain. Current reviews show that retrospective data is insufficient for making firm clinical recommendations. Researchers should focus on standardized dosing and specific cannabinoid profiles to provide clearer answers for perioperative care.
Questioning the Data
Self-reported data in substance use studies must be viewed with caution due to the potential for bias. While the correlation between coping motives and suicidal ideation is significant, it does not establish a causal link. We must consider other confounding factors, such as the severity of the underlying psychiatric condition, before drawing conclusions.
The lack of Level I evidence in the surgical literature means that any current recommendations are based on incomplete information. We should be skeptical of claims that cannabis is a safe alternative to opioids without more rigorous testing. Until the data is more consistent, a conservative approach to perioperative cannabis use is the most logical path.
Observing Use Patterns
If you are caring for someone with a complex mental health condition, pay attention to how they use cannabis. Using it to cope with bad days or negative thoughts about themselves may indicate they are struggling more than they let on. Your observations can be a vital part of their overall care plan.
When a loved one is preparing for surgery, help them have a conversation with their doctor about their cannabis use. Ensuring the surgical team has a complete picture of their habits can prevent complications and lead to a smoother recovery. Your support in managing their pain and mental health is invaluable.
Context is Everything
The primary lesson from these studies is that the context of cannabis use is a major factor in patient outcomes. Whether in a psychiatric or surgical setting, understanding the patient’s motives and history is essential for safe care. This requires a shift from simply tracking use to understanding the underlying reasons.
Clinicians and patients must work together to navigate the current lack of high-quality evidence in many areas of cannabis medicine. By focusing on open communication and individualized care, we can mitigate risks and improve the quality of life for those using cannabis for therapeutic purposes. Knowledge and transparency are our best tools.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
What is covered in this cannabis science & research digest?
This edition reviews 3 verified developments across cannabis policy, regulatory oversight, and clinical science.
How are stories selected for CED digests?
Stories are curated from official primary sources, government agency dockets, and peer-reviewed journals, focusing on practical relevance for patients and clinicians.
Do preliminary reports establish medical efficacy?
No. Observational reports, preprints, and regulatory filings describe emerging trends and require formal clinical trials before treatment efficacy can be claimed.
How should clinicians use these updates?
Clinicians can use these updates to understand patient questions, stay current with state regulations, and maintain evidence-informed counseling.
Where can readers find Dr. Caplan's clinical insights?
Dr. Caplan provides comprehensive clinical perspectives, patient consultations, and educational resources at CEDclinic.com.
Why are multi-topic digests published instead of single stories?
Digests group related updates together to provide a broader thematic overview while preserving important nuances and methodological limits.
What is the primary role of laboratory testing in cannabis policy?
Laboratory testing verifies cannabinoid potency and screens for harmful contaminants like heavy metals, pesticides, and molds to protect consumer health.
How do state regulatory milestones impact patient access?
Administrative milestones establish the licensing rules, product categories, and retail standards that determine how and where registered patients obtain care.
What precautions should families take with medical cannabis at home?
Families should keep all medical cannabis products securely locked in child-resistant containers and clearly labeled to avoid accidental exposure.
How often does CED Clinic publish clinical and policy updates?
CED Clinic publishes regular morning, afternoon, and evening evidence reviews and news digests to keep the community informed.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
